识别2型糖尿病亚型的血液生物标志物:ORIGIN试验报告
研究基于ORIGIN试验7017例参与者,将患者分为五个亚型,采用前向选择逻辑回归从233个心血管代谢蛋白生物标志物中筛选各亚型的独立决定因素,并评估其联合预测各亚型的AUC ROC。共识别25个生物标志物为亚型独立决定因素,各亚型AUC ROC范围不同,除GAD抗体外无其他标志物为SAID决定因素。
要点
- 25个血清生物标志物为2型糖尿病亚型的独立决定因素,可组合用于亚型诊断检测。
- SIDD、SIRD、MOD、MARD的AUC ROC范围分别为0.611-0.734、0.723-0.861、0.672-0.742、0.651-0.751。
- 除GAD抗体外,无其他生物标志物为SAID的决定因素。
核心结论
- 识别出25个血清生物标志物作为2型糖尿病亚型的独立决定因素,可组合成亚型诊断检测。
研究设计与样本
- 基于ORIGIN试验7017例参与者,使用五个临床变量将其分为五个亚型:SAID(n=241)、SIDD(n=1594)、SIRD(n=914)、MOD(n=1595)、MARD(n=2673)。
- 采用前向选择逻辑回归模型从233个心血管代谢蛋白生物标志物中筛选各亚型 vs 其他的独立决定因素,并评估加入标志物后预测各亚型的AUC ROC。
主要发现
- 共25个生物标志物为亚型独立决定因素:SIDD 13个、SIRD 2个、MOD 7个、MARD 11个(均p<4.3×10-5)。
- 生物标志物集(1至25个)的AUC ROC范围:SIDD 0.611-0.734、SIRD 0.723-0.861、MOD 0.672-0.742、MARD 0.651-0.751。
- 除GAD抗体外,无其他生物标志物为SAID的决定因素。
关键数值与推荐
- 模型调整了年龄、性别、种族、C肽水平、糖尿病病程和采血时降糖药物使用。
- SIDD有13个独立决定因素,SIRD有2个,MOD有7个,MARD有11个(均p<4.3×10-5)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Individuals with diabetes can be clustered into five subtypes using up to six routinely measured clinical variables. We hypothesised that circulating protein levels might be used to distinguish between these subtypes. We recently used five of these six variables to categorise 7017 participants from the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial into these subtypes: severe autoimmune diabetes (SAID, n=241), severe insulin-deficient diabetes (SIDD, n=1594), severe insulin-resistant diabetes (SIRD, n=914), mild obesity-related diabetes (MOD, n=1595) and mild age-related diabetes (MARD, n=2673). METHODS: Forward-selection logistic regression models were used to identify a subset of 233 cardiometabolic protein biomarkers that were independent determinants of one subtype vs the others. We then assessed the performance of adding identified biomarkers (one after one, from the most discriminant to the least) to predict each subtype vs the others using area under the receiver operating characteristic curve (AUC ROC). Models were adjusted for age, sex, ethnicity, C-peptide level, diabetes duration and glucose-lowering medication usage at blood collection. RESULTS: A total of 25 biomarkers were independent determinants of subtypes, including 13 for SIDD, 2 for SIRD, 7 for MOD and 11 for MARD (all p<4.3 × 10-5). The performance of the biomarker sets (comprising 1 to 25 biomarkers), assessed through the AUC ROC, ranged from 0.611 to 0.734, 0.723 to 0.861, 0.672 to 0.742, and 0.651 to 0.751, for SIDD, SIRD, MOD and MARD, respectively. No biomarkers other than GAD antibodies were determinants of SAID. CONCLUSIONS/INTERPRETATION: We identified 25 serum biomarkers, as independent determinants of type 2 diabetes subtypes, that could be combined into a diagnostic test for subtyping. TRIAL REGISTRATION: ORIGIN trial, ClinicalTrials.gov NCT00069784.
引用
- Pigeyre M, Gerstein H, Ahlqvist E, et al. Identifying blood biomarkers for type 2 diabetes subtyping: a report from the ORIGIN trial. Diabetologia. 2023. PMID: 36854916. doi:10.1007/s00125-023-05887-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。